...
首页> 外文期刊>American journal of therapeutics >Aminocaproic Acid and Tranexamic Acid Fail to Reverse Dabigatran-Induced Coagulopathy
【24h】

Aminocaproic Acid and Tranexamic Acid Fail to Reverse Dabigatran-Induced Coagulopathy

机译:氨基己酸和宁甲酸不能反向Dabigatran诱导的凝血病

获取原文
获取原文并翻译 | 示例
           

摘要

In recent years, dabigatran has emerged as a popular alternative to warfarin for treatment of atrial fibrillation. If rapid reversal is required, however, no reversal agent has clearly been established. The primary purpose of this manuscript was to evaluate the efficacy of tranexamic acid and aminocaproic acid as agents to reverse dabigatran-induced coagulopathy. Rats were randomly assigned to 6 groups. Each rat received either dabigatran or oral placebo, followed by saline, tranexamic acid, or aminocaproic acid. An activated clotting test was used to measure the coagulopathy. Neither tranexamic acid nor aminocaproic acid successfully reversed dabigatran-induced coagulopathy. In this rodent model of dabigatran-induced coagulopathy, neither tranexamic acid nor aminocaproic acid were able to reverse the coagulopathy.
机译:近年来,Dabigatran被出现为Warfarin的替代方案,用于治疗心房颤动。 但是,如果需要快速逆转,则没有明确建立逆转者。 该稿件的主要目的是评估Tranexamic acid酸和氨基己酸作为药剂以反向Dabigatran诱导的凝血病的疗效。 大鼠随机分配给6组。 每只老鼠接受Dabigatran或口服安慰剂,然后是盐水,促甲酸或氨基己酸。 使用活化的凝血试验来测量凝血病。 既不是冬季酸也不是氨基己酸成功逆转Dabigatran诱导的凝血病。 在这种Dabigatran诱导的凝血病模型的啮齿动物模型中,既不是促氧磷酸也不能逆转凝血病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号